EA201992180A1 - Изомерно чистыеf-меченые тетрагидрофолаты - Google Patents

Изомерно чистыеf-меченые тетрагидрофолаты

Info

Publication number
EA201992180A1
EA201992180A1 EA201992180A EA201992180A EA201992180A1 EA 201992180 A1 EA201992180 A1 EA 201992180A1 EA 201992180 A EA201992180 A EA 201992180A EA 201992180 A EA201992180 A EA 201992180A EA 201992180 A1 EA201992180 A1 EA 201992180A1
Authority
EA
Eurasian Patent Office
Prior art keywords
labeled
isomerically pure
tetrahydrofolates
use during
cells
Prior art date
Application number
EA201992180A
Other languages
English (en)
Inventor
Рудольф Мозер
Виола Грён
Кристина Мюллер
Роже Шибли
Саймон Аметамей
Зильван Босс
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of EA201992180A1 publication Critical patent/EA201992180A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к изомерно чистымF-меченым (6S)- или (6R)-5-метилтетрагидрофолатным радиофармацевтическим средствам, где фенильная группа в структуре фолата была замененаF-меченым N-гетероциклом, предназначенным для применения во время диагностической визуализации in vitro или in vivo клетки или популяции клеток, экспрессирующих рецептор фолата, или для применения во время мониторинга злокачественного новообразования или воспалительных и аутоиммунных заболеваний и их лечения.
EA201992180A 2017-03-20 2018-03-19 Изомерно чистыеf-меченые тетрагидрофолаты EA201992180A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17161884 2017-03-20
PCT/EP2018/056806 WO2018172243A1 (en) 2017-03-20 2018-03-19 Isomerically pure 18f-labelled tetrahydrofolates

Publications (1)

Publication Number Publication Date
EA201992180A1 true EA201992180A1 (ru) 2020-04-23

Family

ID=58387756

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992180A EA201992180A1 (ru) 2017-03-20 2018-03-19 Изомерно чистыеf-меченые тетрагидрофолаты

Country Status (16)

Country Link
US (1) US20200306390A1 (ru)
EP (1) EP3601288B1 (ru)
JP (1) JP7204662B2 (ru)
KR (1) KR102648945B1 (ru)
CN (1) CN110431141B (ru)
AU (1) AU2018237784B2 (ru)
CA (1) CA3057042A1 (ru)
DK (1) DK3601288T3 (ru)
EA (1) EA201992180A1 (ru)
ES (1) ES2893303T3 (ru)
IL (1) IL269059B (ru)
PL (1) PL3601288T3 (ru)
PT (1) PT3601288T (ru)
SG (1) SG11201908679QA (ru)
WO (1) WO2018172243A1 (ru)
ZA (1) ZA201906877B (ru)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008237934B2 (en) 2007-04-11 2014-03-27 Merck & Cie 18F-labelled folates
PT2254890E (pt) * 2008-02-20 2015-07-31 Gnosis Spa Processo para a resolução diastereoisomérica do ácido 5- metiltetra-hidrofólico
US20130034496A1 (en) * 2011-08-04 2013-02-07 University Of Iowa Research Foundation Positron emission tomography tracer
AU2013258027B2 (en) 2012-05-08 2017-11-30 Merck & Cie 18F-labelled follate/antifolate analogues

Also Published As

Publication number Publication date
IL269059B (en) 2021-12-01
DK3601288T3 (da) 2021-07-05
SG11201908679QA (en) 2019-10-30
ZA201906877B (en) 2021-06-30
US20200306390A1 (en) 2020-10-01
WO2018172243A1 (en) 2018-09-27
KR20190130607A (ko) 2019-11-22
PT3601288T (pt) 2021-07-20
JP7204662B2 (ja) 2023-01-16
AU2018237784A1 (en) 2019-11-07
JP2020511477A (ja) 2020-04-16
CN110431141A (zh) 2019-11-08
AU2018237784B2 (en) 2022-04-21
KR102648945B1 (ko) 2024-03-18
IL269059A (en) 2019-11-28
CA3057042A1 (en) 2018-09-27
EP3601288A1 (en) 2020-02-05
PL3601288T3 (pl) 2021-11-08
CN110431141B (zh) 2022-12-30
ES2893303T3 (es) 2022-02-08
EP3601288B1 (en) 2021-04-21

Similar Documents

Publication Publication Date Title
CY1125092T1 (el) Ιατρικη χρηση σχετικα με επεκταση τελομερους
CO2018003477A2 (es) Anticuerpos anti-pd1 y métodos de uso
TR201819802T4 (tr) 18F etiketli folat/antifolat analogları.
CL2017001296A1 (es) Anticuerpos contra cd73 y sus usos
AR107529A1 (es) Compuestos, composiciones y métodos para la estratificación de pacientes de cáncer y su tratamiento
PH12016500656A1 (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
UY36738A (es) Moduladores de tgr5 y métodos de uso de los mismos
PH12017500164A1 (en) Optionally fused heterocyclyl - substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
UY35465A (es) Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret)
MX2016008449A (es) Inhibidores de serina/treonina cinasa.
EA201890013A1 (ru) Способы получения tcr гамма дельтат-клеток
UY29653A1 (es) Nuevos anticuerpos anti-madcam
TN2018000383A1 (en) Pde9 inhibitors for treatment of peripheral diseases.
AR092188A1 (es) ANTICUERPOS HUMANOS PARA GFRa3 Y METODOS PARA SU USO
BR112018004454A2 (pt) nova subpopulação de tregs cd8+cd45rcbaixo e seu uso
CL2015002531A1 (es) Anticuerpos contra quimiocinas cxc pan-elr+
JO3537B1 (ar) أجسام مضادة لييفية أولية لاميلويد بيتا الببتيد ab المحسنة
PH12018500701A1 (en) 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer
NZ741724A (en) Renal cell populations and uses thereof
MX2023000191A (es) Metodos de fabricacion y uso de inhibidores de pde9.
CR20150266A (es) Formulaciones de liberación modificada para oprozomib
BR112018001424A2 (pt) compostos, composição farmacêutica e métodos para o tratamento de uma doença neoplásica, para o tratamento de um distúrbio inflamatório ou distúrbio autoimune, para o tratamento de uma doença neurodegenerativa e para o tratamento de um distúrbio metabólico
CO2019014671A2 (es) Agentes de iarn para la inhibición de la expresión de alfa-enac y métodos de uso
CL2017002326A1 (es) Tratamiento de pacientes con diabetes mellitus tipo 2
EA201992180A1 (ru) Изомерно чистыеf-меченые тетрагидрофолаты